Research prototype, not medical advice.

In a phase 1-2 trial in patients with telomere syndromes, danazol lengthened telomeres (11 of 12 evaluable patients at 24 months) with blood count responses, but with liver and muscle toxicity.

Confidence
Debated
Level of evidence
Randomized clinical trial
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Telomere attritionDanazolTelomere syndromes (dyskeratosis congenita)Telomerase

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports Danazol Treatment for Telomere Diseases
Townsley et al. · New England Journal of Medicine 2016
— Verified